Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

On October 15, 2024 Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, reported the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101 (Press release, Monopar Therapeutics, OCT 15, 2024, View Source [SID1234647204]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights of the patent filing include:

Composition of Matter: Claims cover a family of linkers, as well as Monopar’s uPAR targeting agents linked with these along with therapeutic radioisotopes
Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticals
Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies
"This provisional patent could enable us to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets that we are interested in," commented Andrew Cittadine, Monopar’s Chief Operating Officer. "We also believe that these linkers may be of great interest to others in the industry, opening the door to potential licensing and development collaborations."

"These novel linkers and compositions of matter exemplify Monopar’s passion and commitment to being an innovator in the radiopharma space," said Chandler Robinson, MD, Monopar’s Chief Executive Officer.